<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140672</url>
  </required_header>
  <id_info>
    <org_study_id>B1261003</org_study_id>
    <nct_id>NCT01140672</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects</brief_title>
  <official_title>A Double Blind, 3rd Party Open, Placebo Controlled, Dose Escalating, Parallel Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04634817 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The goals of this study are to evaluate the safety and tolerability of multiple ascending
      doses of PF-04634817 administered orally to healthy adult subjects. In additional, the plasma
      and urinary pharmacokinetics of multiple ascending doses of PF-04634817 administered orally
      to healthy adult subjects will be evaluated. Finally, the effect of multiple doses of
      PF-04634817 on circulating monocytes will be explored.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, supine and standing vital sign measurements, 12-lead ECGs, blood and urine safety tests.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK Day 1: Cmax, Tmax, AUClast, AUCtau at all dose levels. Plasma PK Day 14: Cmax, Tmax, AUClast, AUCtau, AUCinf, t½, CL/F and Vss/F at all dose levels.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau (Day 14) vs. AUCtau (Day 1) - estimate of accumulation ratio; Cmax (Day 14) vs. Cmax (Day 1); Tmax (Day 14) vs. Tmax (Day 1).</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary PK: Aet (amount excreted in urine); Aet% at all doses of PF-04634817 where t = 24 hours on Day 1 and 14; CLr at all doses on Day 14.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic: MCP-1 change from baseline.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: p-ERK Inhibition in human monocytes: percent inhibition of monocyte p-ERK activity relative to the pre-dose baseline value</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MIP-1β stimulated CCR5 receptor internalization: percent inhibition of internalization relative to the pre-dose baseline value</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and percent change in circulating monocytes; Absolute and percent change in CD14+CD16+ monocytes.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (N=10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (N=10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (N=10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-controlled, multiple doses of PF-04634817 at 30 mg per day for 14 days. (2 placebo: 8 active)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (N=10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-controlled, multiple doses of PF-04634817 at 100 mg per day for 14 days. (2 placebo: 8 active)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 (N=10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-controlled, multiple doses of PF-04634817 at 300 mg per day for 14 days. (2 placebo: 8 active)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 (N=10) Optional cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-controlled, multiple doses of PF-04634817 up to 300 mg per day for 14 days. (2 placebo: 8 active)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.</description>
    <arm_group_label>Cohort 1 (N=10)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.</description>
    <arm_group_label>Cohort 2 (N=10)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.</description>
    <arm_group_label>Cohort 3 (N=10)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.</description>
    <arm_group_label>Cohort 4 (N=10)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.</description>
    <arm_group_label>Cohort 5 (N=10)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.</description>
    <arm_group_label>Cohort 6 (N=10) Optional cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female (of non-childbearing potential) subjects between the ages of
             18 and 55 years, inclusive.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease;

          -  Treatment with an investigational drug within 30 days or 5 half-lives (whichever is
             longer) preceding the first dose of study medication;

          -  Use of tobacco- or nicotine-containing products in excess of the equivalent of 5
             cigarettes per day;

          -  Nursing females;

          -  Females of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1261003&amp;StudyName=A%20Multiple%20Dose%20Study%20To%20Determine%20Safety%2C%20Tolerability%2C%20and%20Pharmacokinetics%20Of%20PF-04634817%20In%20Healthy%20Adult%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2010</study_first_submitted>
  <study_first_submitted_qc>June 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2010</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>multiple dosing</keyword>
  <keyword>Diabetic Nephropathies</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

